AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Prospective, multi-center, interventional, randomized, open clinical trial for the treatment
of acute myeloid leukemia with FLT3 mutations customized upon the prognostic parameter PBC